PTC Therapeutics Grants Stock Options and RSUs to New Employees
On September 22, 2026, PTC Therapeutics (NASDAQ: PTCT) announced the approval of non-statutory stock options and restricted stock units for 37 new employees. The inducement grants included options to purchase up to 51,270 shares at $65.96 per share—PTC's closing price on that day—and RSUs covering an additional 37,995 shares. These awards were made under Nasdaq Listing Rule 5635(c)(4) as part of the new hires' compensation packages and are intended to incentivize their employment with PTC. The stock options have a four-year vesting schedule, with 25% vesting after one year and incremental vesting every three months thereafter. The RSUs will also vest over four years in equal annual installments of 25%. Both types of awards are subject to the employees' continued service through each vesting date. PTC is a biopharmaceutical company focused on developing treatments for rare disorders, and this move reflects its ongoing strategy to attract talent while aligning employee interests with long-term shareholder value.
Tickers: $PTCT